PDRG1 (p53 and DNA damage regulated 1) is a 133-residue oncogenic protein that functions as a key regulator of cellular proliferation and stress responses. Mechanistically, PDRG1 operates through multiple pathways: it interacts with methionine adenosyltransferase catalytic subunits to downregulate S-adenosylmethionine synthesis, potentially affecting epigenetic methylation 1, and activates pro-tumorigenic signaling cascades including ATM/p53 2, MEK/ERK/CD44 3, and Wnt pathways 4. PDRG1 expression is selectively induced by genotoxic stress and is significantly upregulated in multiple malignancies including gastric, colorectal, glioblastoma, esophageal, lung, and bladder cancers, correlating with advanced tumor stage, poor differentiation, and lymph node metastasis 5. Clinically, PDRG1 serves as an independent prognostic indicator predicting poor survival outcomes 6, 3. PDRG1 knockdown inhibits tumor cell growth, migration, and invasion while promoting apoptosis and cell cycle arrest across multiple cancer types 2, 6. MicroRNA-214 suppresses PDRG1 expression as a tumor-suppressive mechanism 7. These findings establish PDRG1 as a valuable biomarker and promising therapeutic target for cancer diagnosis and treatment.